How much funding has Umoja raised?

Umoja has raised $363.0M in total funding, most recently a Series C round.

Who are Umoja's investors?

Umoja's investors include DCVC (Data Collab), Cormorant Asset Management, MPM Capital, Double Point Ventures, SoftBank, Qiming Venture Partners USA.

Where is Umoja headquartered?

Umoja is headquartered in Seattle, Washington, United States.

What industry is Umoja in?

Umoja operates in Biotech, Drug Discovery, Life Sciences, Therapeutics.

Umoja

Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells and generate lasting remission.

Seattle, United States · Founded 2019 · $363.0M raised

Headquarters: Seattle, Washington
Employees: 201–500
Founded: 2019
Business Model: B2B

Website: umojabiopharma.com
Total Funding: $363.0M
Last Round: $100.0M Series CJan 2025
Rounds: 4

About

Umoja Biopharma is a clinical-stage biotechnology company pioneering in vivo CAR T cell therapy. Rather than manufacturing CAR T cells outside the body, Umoja's proprietary platform reprograms T cells inside patients, eliminating the costly and time-consuming ex vivo manufacturing process. The company's integrated technology platform is designed to make next-generation immunotherapy cost-effectively accessible to all cancer patients, including those who cannot benefit from current CAR T treatments. Umoja's pipeline targets solid tumors and hematologic malignancies.

Summary

Umoja is a Biotech company based in Seattle, United States, founded in 2019. It has raised $363.0M in total across 4 rounds, most recently a $100.0M Series C round in Jan 2025. Investors include DCVC (Data Collab), Cormorant Asset Management and MPM Capital.

LinkedIn X (Twitter)